Funding announcement
Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa
Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.